BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ConvaTec Extends Leadership Position in Fecal Management Systems with Launch of Flexi-Seal® CONTROL™ FMS


3/5/2013 10:47:05 AM

SKILLMAN, N.J., March 5, 2013 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies, today announced the U.S. launch of Flexi-Seal® CONTROL FMS, extending the company's leadership position in fecal management systems. Flexi-Seal® FMS is used by more hospitals and nurses than any other fecal management system in the world.

Flexi-Seal® CONTROL FMS, an advanced containment device for patients with acute fecal incontinence, is the first and only fecal management system that automatically protects against over-inflation of the device's retention balloon, ensuring an optimal fit and maximum effectiveness.

Fecal incontinence, a common condition affecting patients in intensive care, places a heavy burden on hospitals and carries significant risks to patients. Complications and harmful effects include skin breakdown and the development of pressure ulcers, as well as the spread of C.difficile, a dangerous bacterium, from infectious diarrhea.

"ConvaTec developed Flexi-Seal® CONTROL FMS to provide the most advanced health, economic and environmental benefits for hospitals and patients," said Mark Valentine, President, Americas. "The new system is designed to provide the same skin protection and infection containment benefits as existing Flexi-Seal® systems, plus new features that improve patient care and priced at parity with Flexi-Seal® SIGNAL FMS deliver more value."

The new features of Flexi-Seal® CONTROL FMS include a unique control valve that automatically shuts off once the optimal fill volume of the device's retention balloon is reached. This ensures optimal usage of the device and a secure, individual fit to protect the patient's skin from harmful effluent.

In addition to automatic fill control, Flexi-Seal® CONTROL FMS introduces total odor control combined with infection control, contributing to a better and safer environment for patients, visitors and hospital staff. Unique, end-to-end odor protection is provided by an advanced odor barrier that runs the full length of the tubing and a bag filter that has six times more odor-absorbing capacity, as demonstrated in vitro. The new Privacy Bag also allows clinicians to monitor waste collection without compromising patient privacy.

Flexi-Seal® CONTROL FMS has been proven, in vitro, to contain the spread of C.difficileinfection. In addition, the closed system may help to reduce additional environmental contamination from other deadly pathogens, such as extended-spectrum beta-lactamase (ESBL) producing bacteria and methicillin-resistant Staphylococcus aureaus (MRSA).

About Flexi-Seal® Fecal Management from ConvaTec
Flexi-Seal® FMS is a temporary containment device that has been shown to safely and effectively divert fecal matter, helping protect patients' skin from breakdown. It is the only fecal management system that has been proven, in vitro, to contain the spread of C.difficile infection. Flexi-Seal® FMS is indicated for patients with little to no bowel control and liquid or semi-liquid stool, and can be used for up to 29 consecutive days.

About ConvaTec
ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit www.convatec.com.

®/TM indicates trademarks of ConvaTec Inc.
© 2013 ConvaTec Inc.
AP-013472-US

SOURCE ConvaTec



Read at BioSpace.com

ConvaTec
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES